Lemchukwu Chukwunonye Amaeshi

Lemchukwu Chukwunonye Amaeshi

Auto-generated profile, based on publicly available information

Lemchukwu Chukwunonye Amaeshi

Montefiore Medical Center, Bronx, New York

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Open access
LALemchukwu Chukwunonye Amaeshi
Lemchukwu Chukwunonye Amaeshi
The advent of organ transplantation has given hope to patients with end-stage organ failure. Allograft rejection is a transplant complication and remains a significant cause of transplant-related m...

24 March 2026 in The Oncologist
Verified
Journal Article
Open access
RARose Ihuoma Anorlu
Rose Ihuoma Anorlu
LALemchukwu C Amaeshi
Lemchukwu C Amaeshi
KOKEHINDE OKUNADE
KEHINDE OKUNADE
AOAdeyemi A Okunowo
Adeyemi A Okunowo
EOEphriam O Ohazurike
Ephriam O Ohazurike
AMAnn Murphy
Ann Murphy
The global incidence of cancer is on the rise, with Africa experiencing a particularly steep increase in both cancer incidence and mortality. This upward trend is driven by a combination of factors, including population growth, poverty, aging, urbanization, and the adoption of lifestyles that increase the risk of cancer. It is projected that from 2022 to 2045, the incidence of cancer in Africa will increase by 106.8%, while cancer mortality will rise by 111.7% if no action is taken. In contrast, Europe is expected to see increases of only 22.5% in incidence and 32.2% in mortality. Despite global advancements in cancer care, Africa continues to grapple with significant inequities in access to cancer prevention, diagnosis, and treatment. These disparities are primarily driven by financial barriers, inadequate healthcare infrastructure, and imbalances in the global pharmaceutical market. As a result, we are witnessing a troubling rise in premature deaths and their associated consequences. This paper delves into the escalating public health crisis of cancer in Africa. The authors highlight the urgent need to improve access to essential cancer medicines for all affected individuals. Additionally, the paper calls for policy reforms and a coordinated, collaborative effort among stakeholders—including governments, international organizations, and pharmaceutical companies—to ensure equitable access to treatments and improve outcomes for cancer patients in Africa. Addressing this crisis requires alignment with the sustainable development goals to prevent avoidable deaths.

6 January 2026 in JMIR Cancer
Verified
Journal Article
Open access
LALemchukwu Amaeshi
Lemchukwu Amaeshi
LLLauren Laufer
Lauren Laufer
KFKateryna Fedorov
Kateryna Fedorov
ASAlex Sisto
Alex Sisto
DLDavid Levitz
David Levitz
NSNishi Shah
Nishi Shah
Background: Patients with cancer often face significant financial challenges, known as financial toxicity (FT), which is associated with reduced quality of life. Patients with hematologic malignancies (HMs) are especially vulnerable due to intensive and prolonged treatments, frequent hospital visits, and a high risk of complications. While FT affects many in the general population, it is particularly severe among racial and ethnic minorities, especially those below the poverty line. To our knowledge, no studies have specifically examined FT in this vulnerable group in the United States. Objective: This study aimed to evaluate the severity of FT in patients receiving treatment for HMs in a socioeconomically underserved population, explore sociodemographic factors that may predict the severity of FT, and evaluate the subjective experiences of these patients as they relate to FT. Methods: We conducted a prospective, observational, longitudinal study at the Montefiore Cancer Center’s outpatient department in the Bronx, New York, from October 1, 2022, to October 30, 2023. Participants included either adult patients newly diagnosed (ND) with HMs or those already diagnosed, undergoing cellular therapy (CT). The severity of FT was assessed using the validated Comprehensive Score for Financial Toxicity–Functional Assessment of Chronic Illness Therapy (COST-FACIT) questionnaire. Additionally, an investigator-designed questionnaire was developed to gather sociodemographic data and evaluate the subjective effects of financial burden on patient care. Patients in both the ND and CT groups were followed for 90 days. Data collection occurred at their initial presentation, as well as on days 30 and 90. Results: Ninety patients participated in the study (ND=52 and CT=38). The median age was 59 (IQR 44-66) years, with 27% (n=24) African American and 55% (n=48) Hispanic. Overall, 75% (n=67) of participants experienced some degree of FT, most with mild FT at baseline (day 0, median COST-FACIT score=19.4). In the CT group, FT worsened significantly over time, with a decline in median COST-FACIT scores from 19.9 at day 0 to 15.5 on day 90 ( P =.02). In a multivariable linear regression model, race and ethnicity were a significant predictor of FT burden: identifying as African American or Hispanic was associated with a significantly lower COST-FACIT score (ie, higher FT) compared to non-Hispanic White participants (B=−3.08, P =.04, 95% CI −6.05 to −0.12). Additionally, over half of ND and CT participants reported difficulty affording basic necessities (ND: 28/52, 54%; CT: 23/38, 61%) and concerns regarding transportation access and costs (ND: 26/50, 52%; CT: n=18/38, 47%). Conclusions: FT is prevalent among patients with HMs receiving care in underserved populations, and the burden is significantly higher among African American and Hispanic populations.

1 January 2024 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Closed access
OKOlufunto Olufela Kalejaiye
Olufunto Olufela Kalejaiye
LALemchukwu Chukwunonye Amaeshi
Lemchukwu Chukwunonye Amaeshi
OBOluwole Olugbenga Banjoko
Oluwole Olugbenga Banjoko

1 June 2022 in Annals of Internal Medicine: Clinical Cases
Verified
Journal Article
Open access
LALemchukwu Chukwunonye Amaeshi
Lemchukwu Chukwunonye Amaeshi
CSCarolina Santiago
Carolina Santiago
RVRochelle Dalsan Vaughn
Rochelle Dalsan Vaughn
COChibuzor Franklin Ogamba
Chibuzor Franklin Ogamba
ASAsli Selma Sucu
Asli Selma Sucu
Levetiracetam is a widely used and safe antiepileptic drug, and levetiracetam-induced pancytopenia is an uncommon adverse effect. We present a patient case of a middle-aged man with seizures who de...